for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

121.35USD

Change

2.50(+2.10%)

Volume

1,890,936

Today's Range

119.48

 - 

122.41

52 Week Range

101.55

 - 

122.41

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Abbvie Provides Update On RINVOQ For The Treatment Of Rheumatoid Arthritis In The U.S.

Dec 3 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE PROVIDES UPDATE ON RINVOQ® (UPADACITINIB) FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN THE U.S..ABBVIE - U.S. LABEL FOR RINVOQ WILL NOW INCLUDE INFORMATION ABOUT RISKS OF MALIGNANCY,THROMBOSIS, ADDITION OF MORTALITY & MACE RISKS IN BOXED WARNINGS.ABBVIE INC - SNDAS FOR RINVOQ IN ATOPIC DERMATITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND ULCERATIVE COLITIS REMAIN UNDER REVIEW BY FDA.ABBVIE-RINVOQ INDICATED FOR TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RA WHO HAVE HAD INADEQUATE RESPONSE OR INTOLERANCE TO TNF BLOCKERS.

Abbvie Says Expands Immunology Portfolio In European Union With European Commission Approval Of Skyrizi

Nov 17 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE EXPANDS IMMUNOLOGY PORTFOLIO IN EUROPEAN UNION WITH EUROPEAN COMMISSION APPROVAL OF SKYRIZI.APPROVAL SUPPORTED BY DATA FROM TWO PHASE 3 STUDIES EVALUATING SKYRIZI IN PSORIATIC ARTHRITIS PATIENTS.

U.S. Food And Drug Administration Approves Vuity™ The First And Only Eye Drop To Treat Presbyopia (Age-Related Blurry Near Vision)

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES VUITY™ (PILOCARPINE HCI OPHTHALMIC SOLUTION) 1.25%, THE FIRST AND ONLY EYE DROP TO TREAT PRESBYOPIA (AGE-RELATED BLURRY NEAR VISION).

AbbVie Sees Q4 Adjusted Earnings Per Share Of $3.24 To $3.28

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE INC SAYS HAS NOT YET OBSERVED A SIGNIFICANT IMPACT TO USE OF RHEUMATOID ARTHRITIS DRUG RINVOQ AFTER FDA SAFETY COMMUNICATION.ABBVIE EXEC SAYS COULD SEE NEAR-TERM IMPACT TO NEW PATIENTS STARTS ON RINVOQ IF NEW LABEL RESTRICTS USE TO PATIENTS WHO DO NOT RESPOND TO TNF INHIBITORS.ABBVIE SEES Q4 SALES NEARING $15 BILLION.ABBVIE SEES Q4 ADJUSTED EARNINGS PER SHARE OF $3.24 TO $3.28.ABBVIE CEO SAYS NOT READY TO RE-CONFIRM ITS 2025 SALES GUIDANCE FOR RINVOQ YET, WILL WAIT FOR UPDATED LABEL.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).

Abbvie's Cariprazine Met Primary Endpoint In Phase 3 Study As An Adjunctive Treatment For Major Depressive Disorder

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE'S CARIPRAZINE (VRAYLAR®) MET PRIMARY ENDPOINT IN PHASE 3 STUDY AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER.ABBVIE INC - STUDY 3111-302-001, CARIPRAZINE DEMONSTRATED NUMERICAL IMPROVEMENT IN DEPRESSIVE SYMPTOMS FROM BASELINE.ABBVIE INC - STUDY 3111-301-001, CARIPRAZINE (VRAYLAR®) MET ITS PRIMARY ENDPOINT DEMONSTRATING STATISTICALLY SIGNIFICANT CHANGE FROM BASELINE.ABBVIE INC - SAFETY DATA WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF CARIPRAZINE ACROSS INDICATIONS.ABBVIE INC - INTENDS TO SUBMIT A SNDA WITH FDA FOR EXPANDED USE OF CARIPRAZINE FOR ADJUNCTIVE TREATMENT OF MDD.

Abbvie Announces ABBV-951 Showed Improvement In Controlling Motor Fluctuations In Pivotal Phase 3 Trial

Oct 28 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE ANNOUNCES ABBV-951 (FOSLEVODOPA/FOSCARBIDOPA) SHOWED IMPROVEMENT IN CONTROLLING MOTOR FLUCTUATIONS COMPARED TO ORAL LEVODOPA/CARBIDOPA MEDICATION IN PIVOTAL PHASE 3 TRIAL IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE.ABBVIE INC - SYSTEMIC ADVERSE EVENTS WERE GENERALLY CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF LEVODOPA/CARBIDOPA MEDICATIONS.ABBVIE INC - INFUSION SITE ADVERSE EVENTS WERE MOSTLY NON-SERIOUS AND MILD OR MODERATE IN SEVERITY.ABBVIE - PATIENTS WHO GOT 24 HOURS/DAILY ABBV-951 SHOWED STATISTICALLY SIGNIFICANT INCREASES IN HOURS OF "ON" TIME WITHOUT TROUBLESOME DYSKINESIA.ABBVIE - PIVOTAL PHASE 3 STUDY OF CONTINUOUS, SUBCUTANEOUS INFUSION OF ABBV-951 MET ITS PRIMARY ENDPOINT IN A 12-WEEK STUDY.ABBVIE INC - DATA FROM HEAD-TO-HEAD SUPERIORITY STUDY WILL BE A KEY COMPONENT OF GLOBAL REGULATORY SUBMISSIONS.ABBVIE INC - SIGNIFICANT REDUCTION IN HOURS OF "OFF" TIME WAS ALSO OBSERVED IN STUDY.

Abbvie Receives CHMP Positive Opinion For Risankizumab For The Treatment Of Psoriatic Arthritis

Oct 15 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE RECEIVES CHMP POSITIVE OPINION FOR RISANKIZUMAB (SKYRIZI®) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS IN THE EUROPEAN UNION (EU).

Eurobio Scientific Receives USD 430,000 Milestone Payment From Allergan

Oct 6 (Reuters) - EUROBIO SCIENTIFIC SA <ALERS.PA>::EUROBIO SCIENTIFIC RECEIVES A $430,000 MILESTONE PAYMENT FROM ALLERGAN.TRANSITION TO CLINICAL STAGE OF A MOLECULE DERIVED FROM FORMER COLLABORATION.MILESTONE PAYMENT OF US $ 430,000 AS PART OF AN IND SUBMISSION TO US FDA FOR TRANSITION TO CLINICAL PHASE OF AGN-231868 MOLECULE IN TREATMENT OF DRY EYE SYNDROME.

AbbVie Says FDA Approves Qulipta, Developed For Preventive Treatment Of Migraine

Sept 28 (Reuters) - AbbVie Inc <ABBV.N>::FDA APPROVES QULIPTA™ (ATOGEPANT), THE FIRST AND ONLY ORAL CGRP RECEPTOR ANTAGONIST SPECIFICALLY DEVELOPED FOR THE PREVENTIVE TREATMENT OF MIGRAINE.ABBVIE - QULIPTA DEMONSTRATED STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL RAPID, CONTINUOUS REDUCTIONS IN MEAN MONTHLY MIGRAINE DAYS IN ADULTS.ABBVIE INC - TRIAL SHOWED WHEN TAKING QULIPTA, MAJORITY OF PATIENTS EXPERIENCED BETWEEN A 50-100% REDUCTION IN MONTHLY MIGRAINE DAYS ACROSS 12 WEEKS.

Alvotech Says FDA Defers Action on Application For Proposed Humira Biosimilar

Sept 20 (Reuters) - Alvotech::ALVOTECH PROVIDES UPDATE ON FDA ACTION REGARDING AVT02, PROPOSED HIGH-CONCENTRATION BIOSIMILAR TO HUMIRA® (ADALIMUMAB).ALVOTECH: FDA DEFERRING ACTION ON APPLICATION FOR AVT02, PROPOSED BIOSIMILAR TO HUMIRA, UNTIL FACILITY ASSESSMENTS CAN BE COMPLETED.ALVOTECH: CONTINUES TO WORK WITH FDA TO COORDINATE REQUIRED INSPECTION(S) IN SAFE AND ADEQUATE MANNER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up